ELZASONAN

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H23Cl2N3OS
Molecular Weight	448.409
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure of ELZASONAN

SMILES

CN1CCN(CC1)C2=CC=CC=C2\C=C3/SCCN(C3=O)C4=CC(Cl)=C(Cl)C=C4

InChI

InChIKey=LHYMPSWMHXUWSK-STZFKDTASA-N

InChI=1S/C22H23Cl2N3OS/c1-25-8-10-26(11-9-25)20-5-3-2-4-16(20)14-21-22(28)27(12-13-29-21)17-6-7-18(23)19(24)15-17/h2-7,14-15H,8-13H2,1H3/b21-14-

HIDE SMILES / InChI

Molecular Formula	C22H23Cl2N3OS
Molecular Weight	448.409
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description

Elzasonan (CP 448187) is a serotonin 1B/1D receptor antagonist. Elzasonan was primarily metabolized via oxidative N‐demethylation, N‐oxidation, and aryl hydroxylation. Pfizer was developing elzasonan for the treatment of anxiety and affective disorders however development has been discontinued.

CNS Activity

Originator

Approval Year

PubMed

Patents

Substance Class	Chemical
Record UNII	933PJL964R
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

ELZASONAN

Official Name

English

(2Z)-4-(3,4-DICHLORPHENYL)-2-(2-(4-METHYLPIPERAZIN-1-YL)BENZYLIDENE)THIOMORPHOLIN-3-ONE

Common Name

English

3-THIOMORPHOLINONE, 4-(3,4-DICHLORPHENYL)-2-((2-(4-METHYL-1-PIPERAZINYL) PHENYL)METHYLENE)-, (2Z)-

Common Name

English

elzasonan [INN]

Common Name

English

Showing 1 to 4 of 4 entries

Show entries

Classification Tree

Code System

Code

Agent Affecting Nervous System

NCI_THESAURUS

C66885

Showing 1 to 1 of 1 entries

Show entries

Code System

Code

Type

Description

EPA CompTox

DTXSID7047277

PRIMARY

FDA UNII

933PJL964R

PRIMARY

CAS

205683-28-9

NON-SPECIFIC STEREOCHEMISTRY

PUBCHEM

6914152

PRIMARY

MESH

C556408

PRIMARY

Showing 1 to 5 of 10 entries

Previous1 2Next

Show entries

Related Record

Type

Details


					X38F62RR8L

ELZASONAN HYDROCHLORIDE

PARENT -> SALT/SOLVATE


					67JE11VN82

ELZASONAN CITRATE

SALT/SOLVATE -> PARENT


					X38F62RR8L

ELZASONAN HYDROCHLORIDE

SALT/SOLVATE -> PARENT


					UE9PX4FTL0

5-HYDROXYTRYPTAMINE RECEPTOR 1B

TARGET->ANTAGONIST


					67JE11VN82

ELZASONAN CITRATE

SALT/SOLVATE -> PARENT

Showing 1 to 5 of 7 entries

Previous1 2Next

Show entries

Related Record

Type

Details


					DMT4KZK6LQ

(2Z)-4-(3,4-DICHLOROPHENYL)-2-((5-HYDROXY-2-(4-METHYL-1-PIPERAZINYL)PHENYL)METHYLENE)-3-THIOMORPHOLINONE

METABOLITE -> PARENT

Qualification:

FECAL

Amount:

6.2 % (average)
of dose


					CQY99G9NKE

(2Z)-4-(3,4-DICHLOROPHENYL)-2-((2-(4-METHYL-4-OXIDO-1-PIPERAZINYL)PHENYL)METHYLENE)-3-THIOMORPHOLINONE

METABOLITE -> PARENT

Qualification:

PLASMA

Amount:

5.5 % (average)
Total Radioactivity in Plasma


					45RWT5K59S

3-THIOMORPHOLINONE, 4-(3,4-DICHLOROPHENYL)-2-(1,2,3,4-TETRAHYDRO-2-METHYLPYRAZINO(1,2-A)INDOL-10-YL)-

METABOLITE -> PARENT

Qualification:

PLASMA

Amount:

65.2 % (average)
Total Radioactivity in Plasma


					45RWT5K59S

3-THIOMORPHOLINONE, 4-(3,4-DICHLOROPHENYL)-2-(1,2,3,4-TETRAHYDRO-2-METHYLPYRAZINO(1,2-A)INDOL-10-YL)-

METABOLITE -> PARENT

Comments:

M6 accounted (average of six human subjects) for 5.6% (sum of M5 and M6) of the administered dose in feces

Qualification:

FECAL


					CQY99G9NKE

(2Z)-4-(3,4-DICHLOROPHENYL)-2-((2-(4-METHYL-4-OXIDO-1-PIPERAZINYL)PHENYL)METHYLENE)-3-THIOMORPHOLINONE

METABOLITE -> PARENT

Qualification:

URINE

Amount:

7.8 % (average)
of dose

Showing 1 to 5 of 7 entries

Previous1 2Next

Show entries

Related Record

Type

Details


					933PJL964R

ELZASONAN

ACTIVE MOIETY

Showing 1 to 1 of 1 entries

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Biological Half-life	PHARMACOKINETIC	31.5 hours (average)			ORAL ADMINISTRATION